Patent Issued for Manufacturing optimization of GL-2045, a multimerizing stradomer (USPTO 11795193).

Gliknik Inc. has been granted a patent for an optimized manufacturing method of GL-2045, a recombinant mimetic of intravenous immunoglobulin (IVIG) used in the treatment of autoimmune diseases. The method involves culturing CHO cells, adjusting growth temperature, and utilizing purification techniques to improve cell viability, protein titer, and the percentage of higher-order multimers in GL-2045. The patent also describes a composition comprising a recombinantly produced homodimer and a multimer of the homodimer, which is effective in treating inflammatory, autoimmune, or infectious diseases. The patent was filed by Gliknik Inc. and published in October 2023. [Extracted from the article]